C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter B—Food for Human ConsumptionPart 101—Food LabelingSubpart F—Specific Requirements for Descriptive Claims That Are Neither Nutrient Content Claims nor Health Claims

21 C.F.R. § 101.93 (2026)

Certain types of statements for dietary supplements

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 19 IN 5Y cited 2004–2025 31citing cases
At a glance

Courts have cited this section in 31 opinions since 2004, 19 of them in the last five years.

(a)(1) No later than 30 days after the first marketing of a dietary supplement that bears one of the statements listed in section 403(r)(6) or the Federal Food, Drug, and Cosmetic Act, the manufacturer, packer, or distributor of the dietary supplement shall notify the Office of Dietary Supplement Programs (HFS-810), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, that it has included such a statement on the label or in the labeling of its product. An original and two copies of this notification shall be submitted.

(2) The notification shall include the following:

(i) The name and address of the manufacturer, packer, or distributor of the dietary supplement that bears the statement;

(ii) The text of the statement that is being made;

(iii) The name of the dietary ingredient or supplement that is the subject of the statement, if not provided in the text of the statement; and

(iv) The name of the dietary supplement (including brand name), if not provided in response to paragraph (a)(2)(iii) on whose label, or in whose labeling, the statement appears.

(3) The notice shall be signed by a responsible individual or the person who can certify the accuracy of the information presented and contained in the notice. The individual shall certify that the information contained in the notice is complete and accurate, and that the notifying firm has substantiation that the statement is truthful and not misleading.

(b) Disclaimer. The requirements in this section apply to the label or labeling of dietary supplements where the dietary supplement bears a statement that is provided for by section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the act), and the manufacturer, packer, or distributor wishes to take advantage of the exemption to section 201(g)(1)(C) of the act that is provided by compliance with section 403(r)(6) of the act.

(c) Text for disclaimer. (1) Where there is one statement, the disclaimer shall be placed in accordance with paragraph (d) of this section and shall state:

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

(2) Where there is more than one such statement on the label or in the labeling, each statement shall bear the disclaimer in accordance with paragraph (c)(1) of this section, or a plural disclaimer may be placed in accordance with paragraph (d) of this section and shall state:

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

(d) Placement. The disclaimer shall be placed adjacent to the statement with no intervening material or linked to the statement with a symbol (e.g., an asterisk) at the end of each such statement that refers to the same symbol placed adjacent to the disclaimer specified in paragraphs (c)(1) or (c)(2) of this section. On product labels and in labeling (e.g., pamphlets, catalogs), the disclaimer shall appear on each panel or page where there such is a statement. The disclaimer shall be set off in a box where it is not adjacent to the statement in question.

(e) Typesize. The disclaimer in paragraph (c) of this section shall appear in boldface type in letters of a typesize no smaller than one-sixteenth inch.

(f) Permitted structure/function statements. Dietary supplement labels or labeling may, subject to the requirements in paragraphs (a) through (e) of this section, bear statements that describe the role of a nutrient or dietary ingredient intended to affect the structure or function in humans or that characterize the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, provided that such statements are not disease claims under paragraph (g) of this section. If the label or labeling of a product marketed as a dietary supplement bears a disease claim as defined in paragraph (g) of this section, the product will be subject to regulation as a drug unless the claim is an authorized health claim for which the product qualifies.

(g) Disease claims. (1) For purposes of 21 U.S.C. 343(r)(6), a “disease” is damage to an organ, part, structure, or system of the body such that it does not function properly (e.g., cardiovascular disease), or a state of health leading to such dysfunctioning (e.g., hypertension); except that diseases resulting from essential nutrient deficiencies (e.g., scurvy, pellagra) are not included in this definition.

(2) FDA will find that a statement about a product claims to diagnose, mitigate, treat, cure, or prevent disease (other than a classical nutrient deficiency disease) under 21 U.S.C. 343(r)(6) if it meets one or more of the criteria listed below. These criteria are not intended to classify as disease claims statements that refer to the ability of a product to maintain healthy structure or function, unless the statement implies disease prevention or treatment. In determining whether a statement is a disease claim under these criteria, FDA will consider the context in which the claim is presented. A statement claims to diagnose, mitigate, treat, cure, or prevent disease if it claims, explicitly or implicitly, that the product:

(i) Has an effect on a specific disease or class of diseases;

(ii) Has an effect on the characteristic signs or symptoms of a specific disease or class of diseases, using scientific or lay terminology;

(iii) Has an effect on an abnormal condition associated with a natural state or process, if the abnormal condition is uncommon or can cause significant or permanent harm;

(iv) Has an effect on a disease or diseases through one or more of the following factors:

(A) The name of the product;

(B) A statement about the formulation of the product, including a claim that the product contains an ingredient (other than an ingredient that is an article included in the definition of “dietary supplement” under 21 U.S.C. 321(ff)(3)) that has been regulated by FDA as a drug and is well known to consumers for its use or claimed use in preventing or treating a disease;

(C) Citation of a publication or reference, if the citation refers to a disease use, and if, in the context of the labeling as a whole, the citation implies treatment or prevention of a disease, e.g., through placement on the immediate product label or packaging, inappropriate prominence, or lack of relationship to the product's express claims;

(D) Use of the term “disease” or “diseased,” except in general statements about disease prevention that do not refer explicitly or implicitly to a specific disease or class of diseases or to a specific product or ingredient; or

(E) Use of pictures, vignettes, symbols, or other means;

(v) Belongs to a class of products that is intended to diagnose, mitigate, treat, cure, or prevent a disease;

(vi) Is a substitute for a product that is a therapy for a disease;

(vii) Augments a particular therapy or drug action that is intended to diagnose, mitigate, treat, cure, or prevent a disease or class of diseases;

(viii) Has a role in the body's response to a disease or to a vector of disease;

(ix) Treats, prevents, or mitigates adverse events associated with a therapy for a disease, if the adverse events constitute diseases; or

(x) Otherwise suggests an effect on a disease or diseases.

[62 FR 49886, Sept. 23, 1997, as amended at 62 FR 49867, Sept. 23, 1997; 65 FR 1050, Jan. 6, 2000; 66 FR 17358, Mar. 30, 2001; 66 FR 56035, Nov. 6, 2001; 88 FR 17718, Mar. 24, 2023]
The 20 cases that cite 21 C.F.R. § 101.93 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENJames Kroessler v. CVS Health Corp., 977 F.3d 803 (9th Cir. 2020).
cites § 101.93 4×cited by 80 cases
The case’s holding
The Federal Food, Drug, and Cosmetic Act does not preempt state false advertising claims where the plaintiff alleges that a supplement lacks the claimed effect on human structure or function.
Later courts cite it for
“no amendment would allow the complaint to withstand dismissal as a matter of law.” · 14 citing courts
2
GREENTodd Greenberg v. Target Corp., 985 F.3d 650 (9th Cir. 2021).
cites § 101.93 5×cited by 20 cases
The case’s holding
A structure/function claim on a dietary supplement label describes only a nutrient's general role in the body, so state claims requiring proof of benefit to each consumer are preempted by federal law.
Later courts cite it for
“a 21 disease claim refers to a statement that the product itself can cure or treat a disease.” · 4 citing courts
3
GREENPaul Dachauer v. Nbty, Inc., 913 F.3d 844 (9th Cir. 2019).
cites § 101.93 2×cited by 23 cases
Where it cites § 101.93
“21 C.F.R. § 101.93 (g)(2)(ii). Structure/function claims must meet three requirements: (1) the manufacturer has substantiation that the statement is truthful and not misleading; (2) the statement contains a prominent disclaimer that the Food and Drug Administration (“FDA”) has…”
The case’s holding
The FDCA expressly preempts state law requirements for dietary supplement claims that differ from federal requirements.
Later courts cite it for
“343-1(a)(5) preempts state-law requirements for claims about dietary supplements that differ from the fdca's requirements.” · 2 citing courts
4
GREENSandoval v. PharmaCare US, Inc., 145 F. Supp. 3d 986 (S.D. Cal. 2015).
cites § 101.93 4×cited by 10 cases
Where it cites § 101.93
“) Hence, plaintiff claims, Inten-seX violates FDA regulation 21 C.F.R. § 101.93 , which regulates the claims manufacturers can make on supplement labels, as well as California’s Sherman Food, Drug, and Cosmetic Law (“Sherman Law”), Cal, Health & Safety Code § 109875 et seq.”
5
GREENChristine Vitello v. Natrol, LLC, 50 F.4th 689 (8th Cir. 2022).
cites § 101.93 1×cited by 20 cases
Where it cites § 101.93
“See 21 C.F.R. § 101.93 (c)(2). Second, at the end of the “Supplement Facts” statements: “Consult your healthcare professional prior to use if you have or suspect a medical condition, are taking prescription drugs, or if you are pregnant or lactating.”
Later courts cite it for
“(1) purchased merchandise from the defendant; (2) for personal, family or household purposes; and (3) suffered an ascertainable loss of money or property; (4) as a result of an act declared unlawful under the mmpa.” · 2 citing courts
6
GREENKanfer v. Pharmacare US, Inc., 142 F. Supp. 3d 1091 (S.D. Cal. 2015).
cites § 101.93 2×cited by 13 cases
Where it cites § 101.93
“) Defendant relies on guidance the FDA issued with the final regulation interpreting the distinction between structure/function claims and disease claims, 21 C.F.R. § 101.93 (f)-(g). The guidance explains that “ ‘arouses or increases sexual desire and improves sexual…”
Later courts cite it for
“courts addressing motions to dismiss product-labeling claims routinely take 22 judicial notice of images of the product packaging.” · 2 citing courts
7
GREENHughes v. Ester C Co., 99 F. Supp. 3d 278 (E.D.N.Y. 2015).
cites § 101.93 3×cited by 3 cases
Where it cites § 101.93
“at § 343(r)(6)(B)-(C); see 21 C.F.R. § 101.93 . Section 343(r)(6) expressly prohibits claims that dietary supplements can “diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases” (“disease claim”).”
8
GREENUnited States v. Lane Labs-USA, Inc., 324 F. Supp. 2d 547 (D.N.J. 2004).
cites § 101.93 1×cited by 5 cases
Where it cites § 101.93
“Pursuant to 21 C.F.R. § 101.93 (g)(2), a “statement claims to diagnose, mitigate, treat, cure or prevent disease if it claims explicitly or implicitly, that the product.”
9
NO FLAGArora v. GNC Holdings, Inc., No. 3:19-cv-02414, 2019 WL 6050750 (N.D. Cal. Nov. 15, 2019).
cites § 101.93 7×cited by 0 casesunknown
Where it cites § 101.93
“§§ 321 , 343; 21 C.F.R. §§ 101.93 (d). The plaintiffs also 4 allege that in its marketing of the supplements, GNC “compounds” the harm from omitting the 5 disclaimer by using misleading phrases (such as “clinically studied,” “scientifically designed,” 6 “physician formulated,’…”
10
NO FLAGJ.j, No. 3:24-cv-00311 (S.D. Cal. Oct. 16, 2025).
cites § 101.93 7×cited by 0 casesunknown
Where it cites § 101.93
“21 C.F.R. § 101.93 (g). Manufacturers of 3 dietary supplements are allowed, subject to certain requirements, to make 4 “structure/function” claims about their supplements without prior FDA approval.”
11
NO FLAGLi v. Amazon.com Servs. LLC, 751 F. Supp. 3d 1138 (W.D. Wash. 2024).
cites § 101.93 4×cited by 0 casesunknown
Where it cites § 101.93
“§ 343 (r)(6)(C); see 15 also 21 C.F.R. § 101.93 (c), Dkt. # 1 at 9 ¶ 43.”
12
NO FLAGJ.J v. Ashlynn Mktg. Grp., Inc., No. 3:24-cv-00311 (S.D. Cal. July 1, 2025).
cites § 101.93 4×cited by 0 casesunknown
Where it cites § 101.93
“§ 343 (r)(6)(A); 6 21 C.F.R. § 101.93 (f). On the other hand, a disease claim explicitly or implicitly claims 7 “to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases.”
13
NO FLAGMin Shin v. Umeken USA, Inc., No. 17-56767 (9th Cir. June 3, 2019).
cites § 101.93 3×cited by 0 casesunpublished
Where it cites § 101.93
“Shin’s claim that Umeken made unlawful “disease” representations in violation of 21 C.F.R. § 101.93 and, by extension, the California Sherman Law1 also fails.”
14
GREENMary Beth Montera v. Premier Nutrition Corp., 111 F.4th 1018 (9th Cir. 2024).
cites § 101.93 3×cited by 0 cases
Where it cites § 101.93
“Premier contends that it complied with the Food and Drug Administration’s (FDA) dietary supplement regulation, 21 C.F.R. § 101.93 , and was therefore entitled to § 349(d)’s safe harbor.”
15
NO FLAGGutierrez, No. 2:24-cv-02434 (E.D. Cal. Sept. 22, 2025).
cites § 101.93 3×cited by 0 casesunknown
Where it cites § 101.93
“at 12 (citing cases referencing 21 C.F.R. § 101.93 ). A structure and 6 function claim is permitted on dietary supplement labels, and includes “statements that 7 describe the role of a nutrient or dietary ingredient intended to affect the structure or 8 function in humans or…”
16
NO FLAGNoah Bradach v. Pharmavite, LLC, No. 16-56598 (9th Cir. May 17, 2018).
cites § 101.93 2×cited by 0 casesunpublished
Where it cites § 101.93
“See Gallagher, 2015 WL 1056480 at *6; see also 21 C.F.R. § 101.93 (f). Structure/function claims do not require pre-approval from the Food and Drug Administration (“FDA”) so long as the “manufacturer has substantiation that the statements are truthful and not misleading,…”
17
GREENSanchez v. Nurture, Inc., 626 F. Supp. 3d 1107 (N.D. Cal. 2022).
cites § 101.93 2×cited by 0 casesunknown
Where it cites § 101.93
“21 C.F.R. § 101.93 (f). 23 Defendant cites Andrade-Heymsfield v.”
18
NO FLAGAmado v. Procter & Gamble Co., No. 3:22-cv-05427, 2023 WL 3898984 (N.D. Cal. June 8, 2023).
cites § 101.93 2×cited by 0 casesunknown
Where it cites § 101.93
“22 § 343(r)(6); Regulations on Statements Made for Dietary Supplements Concerning the 23 Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg. 10000 -01, 24 1012 (Jan. 6, 2000) (providing “[i]mplied disease claims do not mention the name of a 25 specific…”
19
NO FLAGWarren v. I-Health, Inc., No. 2:23-cv-01926 (E.D. Cal. Oct. 1, 2024).
cites § 101.93 2×cited by 0 casesunknown
Where it cites § 101.93
“12 Defendant argues the product description at issue is not a disease claim requiring advance 13 FDA approval, but rather a permissible structure-function claim and that federal law preempts 14 plaintiffs’ claims.”
20
NO FLAGJohn Sandoval v. Pharmacare US, Inc., No. 16-56301 (9th Cir. Apr. 5, 2018).
cites § 101.93 1×cited by 0 casesunpublished
Where it cites § 101.93
“§ 343 (r)(6); 21 C.F.R. § 101.93 (g). Therefore, PharmaCare’s alleged failure to obtain approval of IntenseX as an OTC aphrodisiac drug under 21 C.”

Show all 31 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200420142025

One bar per year. Tallest: 6 cases in 2025. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
9th Cir.9S.D. Cal.8N.D. Cal.7E.D. Cal.28th Cir.1D. Mass.1D.N.J.1E.D.N.Y1

The 8 courts with the most citing cases, of 9 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 31 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com